Ocular Hypertension In Clinical Trials: Protecting IOP Endpoints From Execution Risk

In clinical trials for ocular hypertension, a variance of just two mmHg in intraocular pressure (IOP) can be the difference between a validated treatment response and a failed regulatory submission. Because IOP is a longitudinal, operator-dependent measurement, its integrity relies entirely on the rigor of execution across every site and visit. When multi-site studies lack centralized oversight, invisible risks—such as Goldmann applanation tonometry (GAT) technique inconsistency, calibration drift, and unaligned diurnal timing—begin to embed variability into the dataset long before the database lock.

True data integrity requires moving beyond simple protocol definitions to active execution control. This involves standardizing technician certification, enforcing strict visit windows to account for pressure fluctuations, and maintaining audit-ready equipment logs. By addressing these operational gaps during protocol finalization or study startup, sponsors can prevent the costly cycle of repeat assessments and data cleaning. Ultimately, a cohesive strategy that prioritizes high-fidelity measurement at the point of care not only secures regulatory credibility but also enhances the participant experience by reducing the burden of inconsistent or redundant eye exams.